市場調査レポート
商品コード
1268931
超音波気管支内生検の世界市場-2023-2030Global Endobronchial Ultrasound Biopsy Market - 2023-2030 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
超音波気管支内生検の世界市場-2023-2030 |
出版日: 2023年05月02日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
|
世界の超音波気管支内生検市場は、2022年に5億7,670万米ドルに達し、2030年には最大8億3,270万米ドルに達することで有利な成長を遂げると予測されます。同市場は予測期間中(2023年~2030年)、CAGR4.8%で成長しています。肺末梢病変の診断には、ラジアルプローブ気管支超音波生検(RP-endobronchial ultrasound biopsy)やガイドシース(GS)ベースの生検法が頻繁に利用されます。
最近では、肺疾患の精密診断に役立つ低温生検、電磁誘導気管支鏡、超薄膜気管支鏡が開発されています。縦隔LNサンプリングである縦隔鏡は、肺門リンパ節のサンプリングにも使用できる超音波気管支内生検-TBNAよりも侵襲が少なく、軽い鎮静剤で外来処置として行うことができます。
超音波気管支内生検市場では、ここ数年、技術が飛躍的に進歩し、より正確で迅速な結果をもたらす新しいツールや方法が生み出されています。これらの開発により、超音波気管支内生検は、肺がんやその他の呼吸器疾患を特定するための方法として選択されるようになりました。超音波生検は放射線を使わず、痛みもないため、市場は高い成長を遂げると思われます。
超音波気管支内生検市場の成長率は、開腹手術に比べて痛みが少ない、回復が早い、合併症が少ないなど多くの利点があるため、低侵襲手術の需要が高まっているなど、さまざまな要因によって高い伸び率を示しています。超音波気管支内生検の動向は、侵襲性の低い手法であるため、患者とヘルスケア関係者の双方にとって望ましいものとなっています。患者の転帰を改善し、死亡率を下げるためには、肺がんを早期に発見する必要があります。
肺がん有病率の上昇と研究開発が、超音波気管支内生検市場の成長を牽引しています。
超音波気管支内生検の世界市場は、肺がんの有病率の上昇に伴い拡大しています。肺がんの現状2022年報告」によると、5年生存率が大幅に高い(61%)にもかかわらず、早期発見される肺がん症例は26%に過ぎません。しかし、44%の症例は発見があまりにも遅く、わずか7%の症例が生存しているにすぎません。肺がん発生の90%までがタバコの使用に起因しており、長期間の使用は世界的に、特に中国、ロシア、インドなどの発展途上国でのがん発生率を高めると予想されます。
主なプレーヤーは、経気管支吸引針などの技術的に高度な製品の研究開発努力を拡大しています。これは、肺に関連する感染症やがんを適切に検出するための診断ツールに対する需要の高まりの結果として起こっています。現在、複数の企業が診断目的のためにより優れた超音波生検製品の開発に投資し、多くの努力を払っています。
ヘルスケアへの投資の高まりは、メーカーにとって有利な成長見通しを生み出しています。
呼吸器疾患の診断に広く受け入れられつつあり、肺感染症の全体的な有病率が上昇しているため、超音波気管支内生検には大きな市場機会があるのです。診断用の経気管支吸引針や生検鉗子などの製品の需要が求められるため、メーカーは成長のための有益な選択肢を得ることができるでしょう。
肺疾患の正確な検出を支援するために、クライオバイオプシー、超薄膜気管支鏡、電磁誘導気管支鏡などの新技術がつい最近誕生しました。超音波気管支鏡下経気管支リンパ節穿刺法(TBNA)は、肺門リンパ節のサンプリングにも利用され、軽い鎮静剤で外来手術として行うことができますが、縦隔の中で行われる縦隔鏡検査よりも侵入が多くなります。したがって、投資やヘルスケアインフラへの支出の増加が、市場の成長に寄与しています。
超音波内気管支生検は高額であり、地域、医療機関、保険適用によって価格が変わる可能性があります。特に医療費の少ない低開発の国では、患者さんが超音波内気管支生検の費用を法外に感じることがあります。
超音波気管支内生検の料金は、使用する器具、治療そのもの、必要なアフターケアなど、さまざまな費用に分けることができます。医療制度や国によっては、治療費の全額または一部が保険で支払われる場合もあります。
COVID-19の分析には、Pre-COVIDシナリオ、COVIDシナリオ、Post-COVIDシナリオがあり、価格ダイナミクス(パンデミック時およびパンデミック後の価格変動とCOVID前のシナリオとの比較)、需要-供給スペクトル(取引制限、封鎖およびその後の問題による需要と供給のシフト)、政府の取り組み(政府機関による市場、セクター、産業の活性化に関する取り組み)、メーカーの戦略的取り組み(COVID問題を軽減するためにメーカーは何を行ったか)についても解説しています。
ロシアが無法かつ無抵抗なウクライナへの本格的な侵攻を開始し、米国や国連などからロシアへの制裁が行われるようになりました。今回の危機を受け、多くの企業がロシアでの事業を停止し始めています。この制裁は、ロシア市場からの企業の撤退が始まり、世界市場に大きな影響を与えることは間違いないです。金融規制の悪化により、ロシア・ウクライナ戦争は、ロシアの医療機器産業に悪影響を及ぼすと思われます。
The global endobronchial ultrasound biopsy market reached US$ 576.7 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 832.7 million by 2030. The market is growing at a CAGR of 4.8% during the forecast period (2023-2030). To diagnose peripheral pulmonary lesions, radial probe endobronchial ultrasound biopsy (RP-endobronchial ultrasound biopsy ) and guide sheath (GS)-based biopsy methods are utilized frequently.
Cryo biopsy, electromagnetic navigational bronchoscopy, and ultrathin bronchoscopy have recently been developed to aid in the precise diagnosis of lung illnesses. The mediastinal LN sampling, mediastinoscopy, is less invasive than endobronchial ultrasound biopsy -TBNA, which can also be used to sample hilar lymph nodes and can be done as an outpatient procedure with light sedation.
In the endobronchial ultrasound biopsy market, over the past few years, technology has advanced drastically, with new tools and methods being created that give more precision and quicker outcomes. Because of these developments, endobronchial ultrasound biopsy is now the method of choice for identifying lung cancer and other respiratory conditions. The ultrasound biopsy market will see high growth as it doesn't use radiation and is painless.
The endobronchial ultrasound biopsy market growth rate is high owing to various factors such as increasing demand for minimally invasive procedures because they have a number of advantages over open surgeries, such as less pain, quicker recovery, and fewer complications. Endobronchial ultrasound biopsy trend is seen as it is a less invasive technique which makes it desirable for both patients and healthcare professionals. To improve patient outcomes and lower mortality rates, lung cancer must be detected early.
The increasing prevalence of lung cancer and research and development drives the growth of the endobronchial ultrasound biopsy market.
The global market for endobronchial ultrasound biopsy is expanding as a result of the rising prevalence of lung cancer. Only 26% of lung cancer cases are identified at an early stage, despite the fact that the five-year survival rate is substantially higher (61%), according to the State of Lung Cancer 2022 Report. However, 44% of cases are discovered far too late, when just 7% of them survive. Up to 90% of occurrences of lung cancer are attributable to tobacco use, and prolonged usage is expected to increase the incidence of cancer worldwide, especially in developing countries like China, Russia, and India.
Key players are expanding their research and development efforts for technologically advanced products such as transbronchial aspiration needles. This is happening as a result of the rising demand for diagnostic tools for proper detection of lung related infections or cancer. Several firms are currently investing and putting a lot of effort in developing better ultrasound biopsy products for diagnostic purposes.
The growing investments in healthcare create lucrative growth prospects for manufacturers.
There is a sizable market opportunity for endobronchial ultrasound biopsy as it is becoming more widely accepted for the diagnosis of respiratory disorders and because the overall prevalence of lung infections is rising. Manufacturers are going to have profitable choices for growth as demand for products like transbronchial aspiration needles or biopsy forceps for diagnosis will be required.
To assist in the accurate detection of lung diseases, new technologies such as cryo biopsy, ultrathin bronchoscopy, and electromagnetic navigational bronchoscopy were just recently created. The endobronchial ultrasonography biopsy, or TBNA, which may be utilized as well for sampling hilar lymph nodes & can be performed as an outpatient operation with mild sedation, is more intrusive than mediastinoscopy, which takes place inside the mediastinum. Hence, rising investments or healthcare infrastructure spending are contributing to the growth of the market.
An endobronchial ultrasound biopsy can be expensive, and the price can change depending on the area, the medical center, and insurance coverage. In some circumstances, patients may find the expense of an endobronchial ultrasound biopsy to be exorbitant, especially in underdeveloped nations where healthcare spending is minimal.
The price of an endobronchial ultrasound biopsy procedure can be broken down into a number of different costs, including those for the tools used, the treatment itself, and any required aftercare. Depending on the health plan and the nation, insurance may occasionally pay all or part of the cost of the treatment.
The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario and Post-COVID Scenario along with pricing dynamics (including pricing change during and post-pandemic comparing it with pre-COVID scenarios), demand-supply spectrum (shift in demand and supply owing to trading restrictions, lockdown and subsequent issues), government initiatives (initiatives to revive market, sector or industry by government bodies) and manufacturers strategic initiatives (what manufacturers did to mitigate the COVID issues will be covered here).
Russia started its unlawful and unprovoked full-scale invasion of Ukraine, which resulted in sanctions against Russia from the US, the UN, and other nations. In light of the current crisis, many businesses are starting to stop operating in Russia. These sanctions will surely have a significant effect on the worldwide market as businesses start to leave the Russian market. Due to worsening financial restrictions, the Russo-Ukrainian War will have a detrimental effect on the medical device industry in Russia.
The global endobronchial ultrasound biopsy market is segmented based on product type, application, End User and region.
Lung cancer diagnosis segment will dominate the global endobronchial ultrasound biopsy market over the forecast period, owing to the rise in patients with lung cancer. Lung cancer, infections, and other disorders affecting enlarged lymph nodes in the chest can all be identified with endobronchial ultrasonography (EBUS), a minimally invasive but extremely efficient method.
EBUS enables doctors to use a method known as transbronchial needle aspiration (TBNA) to retrieve tissue or fluid samples from the lungs and adjacent lymph nodes without requiring traditional surgery. The samples can be used to identify tumours like lymphoma, diagnose and stage lung cancer, find infections, and diagnose inflammatory diseases that damage the lungs, such as sarcoidosis.
For instance, Olympus offers 19G EBUS-TBNA needles in addition to the 21G, 22G, and 25G needles, which is unmatched in the industry. The business also offers the ViziShot2 FLEX 19G, a second-generation EBUS needle that assists with histology sampling for suspected cases of lymphoma and sarcoidosis while also supplying more tissue for cutting-edge molecular analysis that enables targeted lung cancer treatment.
North America holds 39.8% of market share owing to the strong presence of major players and increasing healthcare infrastructure investment.
Manufacturers have chances to expand their operations in this region because of the rising demand for diagnostic tools for lung infections in North America. The area has many producers and suppliers, and its rapid economic development has raised industrial production of endobronchial ultrasound biopsy, which has increased the demand.
Growth is also fueled by government measures to promote technologically advanced biopsy tools. Another issue is the rapidly expanding population with lung cancer, which has increased demand for cutting-edge, diagnostic and treatment tools. The region is growing as healthcare professionals have good knowledge about the endobronchial ultrasound biopsy tool, and they are adopting it highly for diagnosis of lung related issues among people.
The major global players in the endobronchial ultrasound biopsy market include Olympus Corporation, CLINODEVICE, Medtronic, CONMED Corporation, Boston Scientific Corporation, Medi-Globe GmbH, Serpex Medical, MICRO-TECH (Nanjing) Co., Ltd., Cook Group Incorporated, and ACE Medical Devices Pvt. Ltd. among others.
The global endobronchial ultrasound biopsy market report would provide approximately 53 tables, 54 figures and 195 Pages.
Australia
LIST NOT EXHAUSTIVE